Is pramlintide a GLP-1 drug?

No. It is an amylin analogue, acting at the amylin receptor complex through a satiety pathway distinct from GLP-1's.

Why does human amylin form amyloid but rat amylin does not?

A small number of residue differences in the aggregation-prone region. Pramlintide borrows rat amylin's prolines at those positions.

How does pramlintide differ from cagrilintide?

Pramlintide is short-acting and dosed with meals. Cagrilintide is engineered for weekly administration, which makes weekly combination products possible.

What Is Pramlintide? The First Amylin Analogue

The short answer

Pramlintide is a synthetic analogue of human amylin and the first to reach clinical use. Human amylin aggregates into amyloid fibrils, making it undeliverable; pramlintide substitutes three residues with prolines borrowed from rat amylin, which does not aggregate. Its short half-life required dosing with meals.

Key facts

Class: Amylin analogue
Molecular weight: ~3,949 Da
Molecular formula: C171H267N51O53S2
PubChem CID: 70691388
Parent hormone: Human amylin (37 residues)
Key modification: Proline substitutions from rat amylin
Dosing: With meals (short half-life)
Successor: Cagrilintide (weekly)

The aggregation problem

Human amylin has a strong propensity to self-assemble into amyloid fibrils. This is not merely a formulation nuisance: it is the same process that deposits islet amyloid in the pancreas in type 2 diabetes. A peptide that turns into insoluble fibrils cannot be delivered reliably, so aggregation had to be solved before amylin pharmacology could be used at all.

The solution came from rodents

Rat amylin does not form amyloid, and the difference traces to a small number of residues in the aggregation-prone region. Pramlintide substitutes prolines at those positions, borrowing rat amylin's resistance. Proline disrupts the regular backbone geometry that β-sheet amyloid assembly requires, so the substitution removes the capacity to fibrillise while retaining receptor activity.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

Why it needed meal-time dosing

Pramlintide has a short half-life and no half-life extension technology: no fatty acid, no albumin binding. Amylin's physiological role is meal-associated, so meal-time dosing matched the biology, but it meant multiple injections a day alongside insulin. That practical burden limited uptake regardless of pharmacology.

What changed with cagrilintide

Cagrilintide is engineered for once-weekly administration, which brings amylin into the same dosing rhythm as modern GLP-1 analogues. That is what makes a fixed-dose weekly combination such as CagriSema possible. Pairing a weekly GLP-1 agonist with a meal-time amylin analogue would not be a practical product.

Why pramlintide matters historically

It established that amylin receptor agonism was achievable and tolerable in people, and that the aggregation barrier could be engineered around. Everything in the current amylin combination pipeline (cagrilintide, amycretin) rests on that being settled two decades earlier.

Frequently asked questions

Is pramlintide a GLP-1 drug?: No. It is an amylin analogue, acting at the amylin receptor complex through a satiety pathway distinct from GLP-1's.
Why does human amylin form amyloid but rat amylin does not?: A small number of residue differences in the aggregation-prone region. Pramlintide borrows rat amylin's prolines at those positions.
How does pramlintide differ from cagrilintide?: Pramlintide is short-acting and dosed with meals. Cagrilintide is engineered for weekly administration, which makes weekly combination products possible.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family: GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial, the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6%, though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

What Is Pramlintide? The First Clinical Amylin Analogue